Finanzen von Alaunos Therapeutics Inc (TCRT)TCRTAlaunos Therapeutics Inc

Evaluating the bottom line, Alaunos Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -350.30%, provide a clear picture of how effectively TCRT converts its operational activities into shareholder value.

In the context of the broader market, TCRT competes directly with industry leaders such as REVB and GRI. With a market capitalization of $47.13M, it holds a leading position in the sector. When comparing efficiency, TCRT's gross margin of N/A stands against REVB's N/A and GRI's N/A. Such benchmarking helps identify whether Alaunos Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Alaunos has reported zero revenue in multiple quarters, with a total loss of $952,000 in Q2 2026 and a negative EPS of -0.41. The gross margin is currently at 0% for the latest quarter, indicating severe operational challenges.